-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: The type I interferon signaling pathway plays a role in the pathogenesis of lupus nephritis
.
Anifrugumab targets the type I interferon signaling pathway and is generally well tolerated in patients with systemic lupus erythematosus (SLE) , with efficacy across a range of clinically meaningful endpoints
.
Objective: The type I interferon signaling pathway plays a role in the pathogenesis of lupus nephritis
Methods: This phase II , double-blind study randomly assigned 147 patients ( 1:1:1 ) to receive monthly intravenous anifrugumab basic ( BR , 300 mg ), intensive ( IR , 900 mg × 3 , thereafter 300 mg ) or placebo, concomitantly with standard therapy (oral corticosteroids, mycophenolate mofetil) .
RESULTS: Patients received anifrugumab BR (n=45) , IR (n=51) or placebo (n=49)
Conclusions: Although the primary endpoint was not met, in patients with active lupus nephritis, anifrugumab IR improved endpoint values including complete renal response at 52 weeks compared with placebo .
Source:
Jayne D, Rovin B, Mysler EF , et al .
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Annals of the Rheumatic Diseases2022; 81: 496-506.
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Annals of the Rheumatic Diseases2022; 81: 496-506.
, et al Annals of the Rheumatic Diseases 81: Leave a message here
